NY-ALVAREZ-&-MARSAL
18.1.2023 07:01:35 CET | Business Wire | Press release
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 85 professionals across Brazil, Benelux, Canada, Cayman Islands, China, France, Germany, India, Spain, United Arab Emirates, United Kingdom and the United States, to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their commitment to help clients maximize value and drive change amid ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. Their proven ability to help solve for clients’ complex problems is critical to the firm’s success and growth moving forward.”
Henry Chambers, Hong Kong
Eden Chen, Shanghai
Sally Sun, Hong Kong
Pedro Bortolotto, São Paulo
Marcelo Compte, São Paulo
Rodrigo Domingues, São Paulo
Lilian Giorgi, São Paulo
Rodrigo Hong, São Paulo
Henrique Kanashiro, São Paulo
Rafael Mendonca Rodrigues, São Paulo
Fabio Missiato, São Paulo
Corporate Performance Improvement
Tiffany Guthrie, Houston
Mike Hall, San Francisco
John McKinnis, Dallas
Sam Rudkin, Atlanta
Kenneth Cochran, Charlotte
Jeffrey Dwyer, Chicago
Lakshman Lakshmanan, Dallas
Chad Lusk, Chicago
Joanna Rangarajan, New York
Global Disputes and Investigations
Lee Betteridge, London
Gary Foster, London
EMEA – Performance Improvement
Private Equity Performance Improvement
Nicola Barbini, London
Chris Gobby, London
Britta Mittler, Frankfurt
Till Prinz, Dusseldorf
Tim Veen, Munich
Gerardo Villalba Bello, Madrid
Ysabel Gaspar Zayco, London
Robert Bradbury, London
Dominic Roope, London
Jatin Arora, Dubai
Mark Bennett, Paris
Daran Hopper, London
Dirk Naujokat, Munich
Steve Trainor, London
Diana Wong, London
EMEA Restructuring
Barry Lynch, Grand Cayman
Helen Skeates, London
David Johnston, London
José Miguel Gómez Rivas, Madrid
Bill Ozturk, Dubai
Environmental, Social and Governance (ESG)
Stephanie Weiler, Chicago
JoyAnn Book, Phoenix
Bianca A. Briola Charlotte
David Nidetz, Detroit
Rich Rieger, Chicago
Anup Gandhi, Mumbai
Pranav Sheth, Mumbai
Infrastructure & Capital Projects
Sue Frost, Washington, D.C.
Alan Richard, Washington, D.C.
Private Equity Performance Group
Kent Edgerton, Nashville
Jana Gold, Washington, D.C.
Brad Howard, New York
Larry Thomas, Tampa
Klaus Weisenberger, San Francisco
Daniel Harlan, Washington, D.C
Restructuring & Turnaround (North America)
Taylor Atwood, Dallas
Matthew Davidson, Detroit
Chad Ellison, Calgary
Kamila Khairoullina, New York
Mark Sidorenkov, Phoenix
Jeff Sielinski, Detroit
Michael Zembillas, Atlanta
Simon Bernstein, New York
Stephanie Doughty, Houston
Michael Farkas, New York
Simon Gore, London
Jack Hollyman, London
Jac Emilio Martinez, Miami
Joseph Plati, New York
Brendan Sinnott, New York
Katya Umanskaya, Los Angeles
Global Transaction Advisory Group
Anuj Astir, New York
Nout Brugman, Amsterdam
David Cho, Chicago
Vitor Garcia, Sao Paulo
Jimmy Glenn, Atlanta
Nick Lynch, London
Jai Tandan, Mumbai
Rhett Taylor, Nashville
Nick Thoele, New York
Cedric Zana, Paris
Cole Corbin, New York
Steven Fischoff, Chicago
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 7,000 people across five continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com. Follow A&M on LinkedIn, Twitter, and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005828/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom